By Fineline Cube 
China-based Hong Kong WinHealth Pharma Group this week formally entered into a long-term partnership with Germany’s Merz Therapeutics GmbH, marking a comprehensive upgrade of their existing cooperation. This expanded collaboration signifies a significant enhancement in the strategic relationship between the two companies.
Expanded Collaboration Scope
The partnership has been expanded from the initial two products to include a total of five, now covering prescription drugs, over-the-counter (OTC) medications, consumer brands, and cross-border ventures. This diversification reflects the companies’ commitment to providing a broader range of healthcare solutions.
Geographic Expansion
Geographically, the collaboration now extends beyond Mainland China to include Hong Kong, Macau, and Taiwan, significantly increasing the patient reach and market coverage of the products.
Product Portfolio Enhancement
Under the renewed agreement, the successful commercialization of Hepa-Merz (L-ornithine L-aspartate) and Contractubex (heparin sodium/allantoin gel) in Mainland China will continue. Additionally, licensing rights for these products will be extended to the new regions. The partnership now also encompasses three new therapies: PK-Merz (amantadine hydrochloride) for Parkinson’s disease management, Pantogar, a clinically-proven hair growth supplement, and an additional heparin sodium/allantoin gel formulation for skin care.-Fineline Info & Tech